Antidepressants

Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder

Retrieved on: 
Tuesday, December 1, 2020
Antidepressants, Management of depression, Bupropion/dextromethorphan, Major depressive disorder, Clinical medicine, Medicine, Health care, Martin Keller

Safety results discussed below include all patients enrolled in the COMET trial.

Key Points: 
  • Safety results discussed below include all patients enrolled in the COMET trial.
  • Efficacy results from the overall COMET trial presented below are for de novo patients only (n=611).
  • Maintenance of efficacy results for roll-over patients were similar, demonstrating sustained efficacy over 12 months, and will be presented in future scientific publications.
  • COMET (Clinical Outcomes with NMDA-based Depression Treatment) was a Phase 3, open-label trial to evaluate the long-term safety and efficacy of AXS-05 in patients with major depressive disorder (MDD).

Global Treatment Resistant Depression Pipeline Insight Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 11, 2020
Biotechnology, General Health, Other Health, Health, Pharmaceutical, Major depressive disorder, Psychiatric diagnosis, Health sciences, Health, Medicine, Antidepressants, Combination drugs, Evolutionary biology, Pharmaceuticals policy

The "Treatment Resistant Depression - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Treatment Resistant Depression - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Treatment Resistant Depression - Pipeline Insight, 2020," report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Treatment Resistant Depression pipeline landscape.
  • This segment of the Treatment Resistant Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery.
  • phase III include Axsome Therapeutics and others
    Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Klarisana Brings Revolutionary Mental Health Treatment to Westminster, Colorado

Retrieved on: 
Monday, November 9, 2020
Drugs, Psychoactive drugs, Branches of biology, Ketones, Amines, Antidepressants, Nicotinic antagonists, Sedatives, Ketamine, Mental health, Pain, Medicaid

With their innovative use of intramuscular ketamine treatment, Klarisana stands poised to make this cutting-edge treatment more accessible than ever before.

Key Points: 
  • With their innovative use of intramuscular ketamine treatment, Klarisana stands poised to make this cutting-edge treatment more accessible than ever before.
  • The team at Klarisana recognize that now more than ever, the rising rates of those struggling with mental health cannot be ignored.
  • Klarisana is the first ketamine-based provider to work in-network with Medicaid in the state of Colorado, making this revolutionary treatment accessible to a cascade of new people who otherwise might not have received this innovative treatment for their condition.
  • Since 2015, Klarisana have been pioneers of ketamine therapy for the treatment of mental health and pain conditions.

Minerva Neurosciences to Present at Jefferies Virtual London Healthcare Conference

Retrieved on: 
Monday, November 9, 2020
Psychoactive drugs, Antidepressants, Hypnotics, Seltorexant, Chemical compounds, 5-HT2A antagonists, Drugs, Roluperidone

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).

Key Points: 
  • WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020 at 12:55 p.m. GMT (7:55 a.m. EST).
  • The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Companys web site, http://ir.minervaneurosciences.com .
  • Minervas portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia; a potential royalty stream from seltorexant (MIN-202 or JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinsons disease.
  • Minervas common stock is listed on the NASDAQ Global Market under the symbol NERV.For more information, please visit www.minervaneurosciences.com .

Axsome Therapeutics to Present Data from the ADVANCE-1 Trial of AXS-05 in Alzheimer’s Disease Agitation at the 13th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

Retrieved on: 
Tuesday, November 3, 2020
Drugs, Psychoactive drugs, Branches of biology, Antidepressants, Combination drugs, NMDA receptor antagonists, Nicotinic antagonists, Bupropion/dextromethorphan, Dextromethorphan, Bupropion, NMDA receptor, Major depressive disorder

AXS-05 is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimers disease agitation, major depressive disorder, and other central nervous system (CNS) disorders.

Key Points: 
  • AXS-05 is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimers disease agitation, major depressive disorder, and other central nervous system (CNS) disorders.
  • AXS-05 consists of a proprietary formulation and dose of dextromethorphan and bupropion and utilizes Axsomes metabolic inhibition technology.
  • AXS-05 is covered by more than 42 issued U.S. and international patents which provide protection out to 2034.
  • AXS-05 is being developed for major depressive disorder (MDD), Alzheimers disease (AD) agitation, and as a treatment for smoking cessation.

Klarisana Launches Innovative New Intramuscular Ketamine Initiative for Mood and Pain Disorders

Retrieved on: 
Monday, November 2, 2020
Drugs, Psychoactive drugs, Branches of biology, Chloroarenes, NMDA receptor antagonists, Amines, Antidepressants, Nicotinic antagonists, Ketamine, Intramuscular injection, Injection, Pain

DENVER, Nov. 2, 2020 /PRNewswire/ --Klarisana is now offering cutting-edge intramuscular ketamine treatment for mental health conditions and chronic pain.

Key Points: 
  • DENVER, Nov. 2, 2020 /PRNewswire/ --Klarisana is now offering cutting-edge intramuscular ketamine treatment for mental health conditions and chronic pain.
  • Switching to intramuscular ketamine treatment allows Klarisana to streamline the entire process, making the treatment more accessible and affordable than ever before.
  • Through offering intramuscular ketamine treatments, Klarisana intends to play their part in reducing the symptoms of mental health conditions in society at large.
  • Though intravenous ketamine infusions have been popular over the last several years, intramuscular ketamine injections may indeed be the future of the treatment.

Sage Therapeutics Announces Positive Interim, Topline Zuranolone Safety and Tolerability Data from Open-Label SHORELINE Study in Patients with MDD

Retrieved on: 
Thursday, October 15, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical trials, Branches of biology, Biology, Magnesium, Magnesium in biology, Physiology, Plant physiology, Antidepressants, the SHORELINE Study, Major Depressive Disorder, Zuranolone, Sage Therapeutics

This clinical study was designed to naturalistically follow patients with major depressive disorder (MDD) and evaluate the safety and tolerability of zuranolone 30 mg in adults for up to one year.

Key Points: 
  • This clinical study was designed to naturalistically follow patients with major depressive disorder (MDD) and evaluate the safety and tolerability of zuranolone 30 mg in adults for up to one year.
  • Sages Phase 3 SHORELINE Study is evaluating the safety and tolerability of zuranolone 30 mg and 50 mg in adults 18-75 who have MDD as defined by a baseline HAMD-17 total score 20.
  • Initial Experience with Zuranolone 50 mg Dosing:
    In May 2020, standard dosing with zuranolone in the SHORELINE Study was increased to 50 mg.
  • The SHORELINE Study (217-MDD-303) is a Phase 3, open-label, 1-year longitudinal study evaluating the safety, tolerability, and need for repeat dosing with zuranolone in adults with MDD.

Osmind and Caretaker Medical Establish Market-Leading Partnership

Retrieved on: 
Friday, October 9, 2020
Technology, Mental health, Mobile, Wireless, Other Technology, Software, Other Health, Health, General Health, Data management, Drugs, Psychoactive drugs, Branches of biology, Antidepressants, Sedatives, Amines, Chloroarenes, Nicotinic antagonists, Ketamine, Electrocardiography

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    The partnership was established to maximize the quality of care that ketamine and other mental health practitioners deliver to their patients.
  • Osmind and Caretaker have established a premium data integration unlike any other that allows for the capture and direct EHR upload of continuous, real-time patient data from Caretaker devices such as beat-by-beat blood pressure, heart rate, respiratory rate, oxygen saturation, 3 lead ECG, and more.
  • "We are thrilled to announce our partnership with the market leader in ketamine and treatment-resistant health, Osmind, to deliver the most robust, comprehensive joint solution for ketamine practices care delivery, said Jeff Pompeo, the president & CEO of Caretaker Medical.
  • Jimmy Qian, the co-founder and COO of Osmind, added, We are very excited about our partnership with Caretaker.

OWP Pharmaceuticals Announces IND Approval for the First-Ever Liquid Oral Suspension Formulation of Quetiapine Fumarate for the Treatment of Schizophrenia and Bipolar Disorder

Retrieved on: 
Wednesday, October 7, 2020
Psychoactive drugs, Receptor antagonists, Chemical compounds, RTT, Atypical antipsychotics, Mood stabilizers, Piperazines, Antidepressants, Quetiapine, Antipsychotic, Bipolar I disorder, Bipolar II disorder

OWP announced today that it has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the first-ever liquid formulation of quetiapine fumarate.

Key Points: 
  • OWP announced today that it has received approval for its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for the first-ever liquid formulation of quetiapine fumarate.
  • Quetiapine fumarate is an atypical antipsychotic and the tablets, for oral use, were first approved in the U.S. in 1997.
  • In schizophrenia, quetiapine fumarate is indicated for treatment in adolescents aged 13 to 17 years and adults.
  • It is also indicated as monotherapy for the acute treatment of depressive episodes in adult patients with bipolar I and bipolar II disorder.

Dr. Ashraf Hanna's Innovative Ketamine Protocol Delivers a Complete Sustained Remission in a Patient with Depression and Suicidal Ideation

Retrieved on: 
Tuesday, October 6, 2020
Drugs, Psychoactive drugs, RTT, Branches of biology, Psychiatric diagnosis, Antidepressants, Amines, Ketamine, Treatment-resistant depression, Post-traumatic stress disorder, Selective serotonin reuptake inhibitor, Obsessive–compulsive disorder

Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.

Key Points: 
  • Many prominent psychiatrists describe Ketamine as fast and effective with results in a matter of days or hours which is a huge advantage over traditional SSRIs.
  • IV Ketamine therapy is only reserved for those patients that have treatment-resistant depression and have failed conventional therapy.
  • I then wanted to expand the treatment for PTSD, depression, bipolar depression and obsessive compulsive disorders.
  • For more information regarding IV Ketamine Infusion therapy for Depression and PTSD , please visit: https://www.ivketamine.com orcall 727-538-2646